ATR · Aptargroup, Inc.
Price & Indicators
Up next
AI Brief
TL;DR.
AI-generated from the earnings call and 8-K · may contain errors · not investment advice
Ask ALVIS about this →Equibles Rating
blended score · not investment adviceBlended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.
Guidance & track record
Guidance from company 8-Ks · delivered figures from as-reported statements · no analyst estimates involved.
Technicals
trend & momentum for long-term holders BuyIllustrative technical + ownership context — a signal mix, not investment advice.
Key metrics
the company's own KPIs, from its earnings releases, calls, and filings| Metric | Latest | Period | YoY |
|---|---|---|---|
| Adjusted earnings per share non-GAAP | $2.61 | six months ended June 30, 2026 | -54.5% |
|
|
|||
| Adjusted EBITDA margin non-GAAP | 20.7% | Q2 2026 | — |
|
|
|||
| Beauty Adjusted EBITDA margin non-GAAP | 12.2% | Q2 2026 | — |
|
|
|||
| Closures Adjusted EBITDA margin non-GAAP | 14.9% | Q2 2026 | — |
|
|
|||
| Core sales growth non-GAAP | 1% | six months ended June 30, 2026 | -50.0% |
|
|
|||
| Pharma Adjusted EBITDA margin non-GAAP | 33.6% | Q2 2026 | — |
|
|
|||
| Share repurchases and dividends | $212M | six months ended June 30, 2026 | -56.4% |
|
|
|||
| Capital expenditures as a percentage of sales | 7% | the year ended December 31, 2025 | — |
| Free cash flow non-GAAP | $303M | the year ended December 31, 2025 | — |
| Leverage ratio | 1.38 | as of December 31, 2025 | — |
| Share repurchase authorization | $600M | the fourth quarter | — |
Figures exactly as the company stated them · click a metric with a to chart its history · period links open the stating document · "call" marks figures stated on the earnings call, "filing" figures stated in the 10-K/10-Q · YoY needs the prior-year figure on file
Versus peers
Medical Instruments & Supplies — same industry group| Company | Mkt cap | YTD | Rev growth Y/Y | P/E | Short % shares |
|---|---|---|---|---|---|
|
ATR
this stock
Aptargroup, Inc.
|
$8.69B | +13.4% | +5.4% | 24.7 | 2.9% |
|
ISRG
Intuitive Surgical Inc
|
$132.55B | -33.8% | +20.5% | 43.1 | 1.9% |
|
MDLN
Medline Inc.
|
$48.20B | -12.7% | +11.5% | — | 2.2% |
|
BDX
Becton Dickinson & Co
|
$47.02B | +13.4% | +8.2% | 64.9 | 3.8% |
|
ALC
Alcon Inc
|
$34.42B | -10.0% | +10.5% | — | 2.7% |
Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding
At a glance
key data from every sectionPerformance
| 5D | 20D | 120D | MTD | YTD | |
|---|---|---|---|---|---|
| ATR | +0.7% | +10.5% | -1.6% | +2.1% | +13.4% |
| SPY | +5.5% | +3.3% | +11.3% | +3.1% | +12.9% |
| vs SPY | -4.8% | +7.2% | -12.9% | -1.0% | +0.5% |
Capital returns
Dividends per share over the trailing 365 days by ex-date · buyback figures as last reported in SEC filings ("spent" derived as authorized − remaining; when several programs run concurrently, authorized is their combined total per the newest filing) · components shown separately — trailing-year buyback spend isn't tracked, so no combined shareholder yield is derived.